Novo Nordisk Stock Rises

Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug.
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'
Key Takeaways Novo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts upgraded the stock.The analysts upgraded the Ozempic obesity drugmaker to a "buy,
Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition
Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products
UBS Upgrades Novo Nordisk A (NVO)
Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst Price Forecast Suggests 61.15% Upside As of December 23, 2024, the average one-year price target for Novo Nordisk A is $137.
Novo Nordisk Stock Jumps on Upgrade to 'Buy'
Novo Nordisk stock has erased 40.7% over the last six months, worsened by a nearly 20% bear gap back in late December following an update on the company's weight loss drug CagriSema. Now "oversold," NVO's 14-day relative strength index (RSI) ranks at 15.

Trump, Greenland and Ozempic

24/7 Wall St5h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Ozempic Company Responds After Trump Tariff Threats on Denmark
Trump threatened "very high" tariffs on Denmark amid Greenland dispute, raising fears of higher prices for Danish pharmaceuticals.
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...
5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher
Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...
Novo, Eli Lilly to dominate global pharma sales in 2025: report
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
Ozempic, Trulicity among Medicare's priciest drugs, report finds
Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...
Ozempic ‘microdosing’ is gaining popularity — but is it effective?
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.
FierceBiotech3d
Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...